Sign in
Taking people in United StatesPhase 3

Monthly Berobenatide Injections for Sleep Apnea and Excess Weight in Breathing Machine Users

Tests berobenatide injections against placebo in adults with sleep apnea and excess weight.

Key facts

Who runs it
Pfizer
Where
Bradenton, Cullman, Dallas, Little Rock, Maplewood, Riverside, Southfield, and Tomball, United StatesSee the 8 sites
Trial code
Registry title
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Status
Recruiting
Phase
Phase 3
People taking part
258 people, planned
Started
17 Sept 2026
Expected to end
18 Jun 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Berobenatide
  • Placebo
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe obstructive sleep apnea and overweight or obesity who already use a breathing machine (PAP). Some people get berobenatide and some get placebo, as a monthly injection under the skin.

Age
18 years or older
Sex
All sexes can join
Disease stage
Moderate to severe obstructive sleep apnea (OSA) that was diagnosed before; body mass index (BMI) of 27 kg/m² or higher at screening
Earlier treatment
Must be using positive airway pressure (PAP) therapy for OSA, and expect to keep using it during the study

Main reasons for not taking part

  • Body weight changed by more than 5% in the 90 days before screening
  • Any type of diabetes (resolved gestational diabetes is allowed)
  • History of acute or chronic pancreatitis
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Other sleep breathing problems besides OSA, such as central sleep apnea or obesity hypoventilation syndrome

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Body mass index (BMI) ≥27 kg/m² at screening
  • Previously diagnosed with moderate to severe obstructive sleep apnea (OSA)
  • Ongoing positive airway pressure (PAP) therapy for obstructive sleep apnea that is expected to continue during the study

Who cannot take part

  • Self-reported body weight change of more than 5% within 90 days prior to screening
  • Diagnosis of any type of diabetes (resolved gestational diabetes is permitted)
  • History of acute or chronic pancreatitis
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) Sleep-disordered breathing conditions other than obstructive sleep apnea that could interfere with study assessments or interpretation of results (eg, central sleep apnea, mixed sleep apnea, Cheyne-Stokes respiration, obesity hypoventilation syndrome, or significant craniofacial abnormalities)

Where in United States

  • DM Clinical ResearchBradenton, United StatesTaking people
  • Cullman Clinical TrialsCullman, United StatesTaking people
  • Velocity Clinical Research, DallasDallas, United StatesTaking people
  • Preferred Research Partners, IncLittle Rock, United StatesTaking people
  • Headlands Research-Twin CitiesMaplewood, United StatesTaking people
  • Probe Clinical Research CorporationRiverside, United StatesTaking people
  • Revive Research Institute, IncSouthfield, United StatesNot yet recruiting
  • DM Clinical ResearchTomball, United StatesNot yet recruiting

About the trial

What the trial wants to find out

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who use a breathing machine (positive airway pressure [PAP] machine).

Read full original descriptionShow less

People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.

During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.

The 2 groups in the trial

  • Treatment ArmTreatment being tested

    Participants will receive berobenatide by Subcutaneous Injection.

    Treatment: Berobenatide

  • PlaceboPlacebo, for comparison

    Participants will receive matching placebo by Subcutaneous Injection.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)
Plain-language title
Monthly Berobenatide Injections for Sleep Apnea and Excess Weight in Breathing Machine UsersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
5 November 2026